{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=14", "query": { "condition": "Malignant Tumor of the Breast", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 618, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumor+of+the+Breast&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:24:14.753Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02038218", "title": "Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Brain Tumors", "Metastatic Malignant Neoplasm to Brain" ], "interventions": [ { "name": "4-Demethyl-4-cholestryloxycarbonylpenclomedine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DEKK-TEC, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2013-09", "completion_date": "2020-08", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Lansing, Michigan • Houston, Texas", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Lansing", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038218" }, { "nct_id": "NCT01037790", "title": "Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Solid Tumor", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Adult Central Nervous System Germ Cell Tumor", "Adult Teratoma", "Benign Teratoma", "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "Familial Testicular Germ Cell Tumor", "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Male Breast Cancer", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Monodermal and Highly Specialized Teratoma", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Extragonadal Seminoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Melanoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Rectal Cancer", "Stage III Extragonadal Non-seminomatous Germ Cell Tumor", "Stage III Extragonadal Seminoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Extragonadal Non-seminomatous Germ Cell Tumor", "Stage IV Extragonadal Seminoma", "Stage IV Melanoma", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Rectal Cancer", "Testicular Immature Teratoma", "Testicular Mature Teratoma" ], "interventions": [ { "name": "PD-0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2009-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037790" }, { "nct_id": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1310", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2023-08-17", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 15, "location_summary": "Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785741" }, { "nct_id": "NCT06120283", "title": "BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Breast Cancer", "Metastatic Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Hormone Receptor Positive Malignant Neoplasm of Breast", "HER2-negative Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Anti-Diarrheal Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2023-12-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 9, "location_summary": "Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120283" }, { "nct_id": "NCT03630354", "title": "EXERCISING TOGETHER for Couples Coping With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Carcinoma", "Colorectal Carcinoma", "Malignant Solid Neoplasm", "Prostate Carcinoma", "Stage I Colorectal Cancer AJCC v8", "Stage I Prostate Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Exercise Intervention (supervised)", "type": "BEHAVIORAL" }, { "name": "Exercise Intervention (unsupervised)", "type": "BEHAVIORAL" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 496, "start_date": "2019-01-18", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630354" }, { "nct_id": "NCT04439175", "title": "Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Taselisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-02-25", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439175" }, { "nct_id": "NCT01869192", "title": "Phase II Trial for Large ER-Negative Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm of Female Breast" ], "interventions": [ { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 72, "start_date": "2003-03-05", "completion_date": "2010-08-21", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01869192" }, { "nct_id": "NCT02324387", "title": "Tc99m Sestamibi Molecular Breast Imaging", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Molecular Breast Imaging (MBI)", "type": "PROCEDURE" }, { "name": "Tc99m sestamibi", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 96, "start_date": "2015-06-15", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02324387" }, { "nct_id": "NCT02192333", "title": "Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Cancer Survivor", "Depression", "Fatigue", "Leukemia", "Lymphoma", "Malignant Bone Neoplasm", "Malignant Digestive System Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Pain", "Sleep Disorder", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Management of Therapy Complications", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telephone-Based Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 390, "start_date": "2015-08-03", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192333" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-14T01:24:14.753Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" } ] }